血液学の最新論文（2019年7月前半リリース分）New reports on Hematology
Leukemia
- Blood Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL). Blood. 2019 Jul 10. pii: blood.2019000402. doi: 10.1182/blood.2019000402. Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch I, Haferlach C, Kubicek S, Mayerhoefer M, Hopfinger G, Jaeger U, Dearden C
- Blood Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 Jul 10. pii: blood.2019000490. doi: 10.1182/blood.2019000490. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC
- Blood Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia. Blood. 2019 Jul 10. pii: blood.2019000239. doi: 10.1182/blood.2019000239. Lucena-Araujo AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR MD, Koury LCA, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria AB, Kerbauy FR, Chauffaille ML, Bendit I, Rocha V, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk P, Lo Coco F, Sanz MA, Berliner N, Rego EM
- Blood PRDM16s transforms megakaryocyte-erythroid progenitors to acute myeloid leukemia-initiating cells. Blood. 2019 Jul 3. pii: blood.2018888255. doi: 10.1182/blood.2018888255. Hu T, Morita K, Hill MC, Jiang Y, Kitano A, Saito Y, Wang F, Mao X, Hoegenauer KA, Morishita K, Martin JF, Futreal PA, Takahashi K, Nakada D
- Blood Quest of biomarkers for venetoclax-treated CLL. 134(2):97-98 Rossi D
- Blood Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. 134(2):111-122 Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF
- Blood Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. 134(1):44-58 van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW
- Blood RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. 134(1):59-73 Mill CP, Fiskus W, DiNardo CD, Qian Y, Raina K, Rajapakshe K, Perera D, Coarfa C, Kadia TM, Khoury JD, Saenz DT, Saenz DN, Illendula A, Takahashi K, Kornblau SM, Green MR, Futreal AP, Bushweller JH, Crews CM, Bhalla KN
- Blood Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. 134(1):85-89 Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S
- Br J Haematol Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia. Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089. Domínguez-Pinilla N, Martínez-Zamorano E, Campos-Martín Y, Algara Plana P, Ignacio González-Granado L, Zamora Gómez M, Mollejo Villanueva M
- Br J Haematol Adult hypodiploid B-acute lymphoblastic leukaemia and stem cell transplantation. 186(2):205-206 Wiernik PH
- Br J Haematol Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. 186(2):220-233 Man S, Henley P
- Br J Haematol Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia – an updated meta-analysis. 186(2):234-242 Vidal L, Gurion R, Shargian L, Dreyling M, Gafter-Gvili A
- Br J Haematol Anthropometric factors and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis. 186(2):243-254 Teras LR, Patel AV, Carter BD, Rees-Punia E, McCullough ML, Gapstur SM
- Br J Haematol The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. 186(2):263-268 Ribera J, Granada I, Morgades M, Vives S, Genescà E, González C, Nomdedeu J, Escoda L, Montesinos P, Mercadal S, Coll R, González-Campos J, Abella E, Barba P, Bermúdez A, Gil C, Tormo M, Pedreño M, Martínez-Carballeira D, Hernández-Rivas JM, Orfao A, Martínez-López J, Esteve J, Bravo P, Garcia-Guiñon A, Debén G, Moraleda JM, Queizán JA, Ortín X, Moreno MJ, Feliu E, Solé F, Ribera JM; PETHEMA Group, Spanish Society of Haematology
- Br J Haematol Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. 186(2):274-285 Horton TM, Whitlock JA, Lu X, O'Brien MM, Borowitz MJ, Devidas M, Raetz EA, Brown PA, Carroll WL, Hunger SP
- Br J Haematol Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients. 186(2):300-310 Folta A, Culen M, Jeziskova I, Herudkova Z, Tom N, Hlubinkova T, Janeckova V, Durinikova A, Vydra J, Semerad L, Dvorakova D, Remesova H, Cerovska E, Cetkovsky P, Jindra P, Szotkowski T, Zak P, Mayer J, Racil Z
- Br J Haematol Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. 186(1):54-59 Cayssials E, Jacomet F, Piccirilli N, Lefèvre L, Roy L, Guilhot F, Chomel JC, Leleu X, Gombert JM, Herbelin A, Barbarin A
- Haematologica Progression of progenitor B cell leukemia is associated with alterations of the bone marrow micro-environment. Haematologica. 2019 Jul 11. pii: haematol.2018.214031. doi: 10.3324/haematol.2018.214031. Ahsberg J, Xiao P, Okuyama K, Somasundaram R, Strid T, Qian H, Sigvardsson M
- Haematologica Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2019 Jul 11. pii: haematol.2018.214882. doi: 10.3324/haematol.2018.214882. Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA
- Haematologica TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia. Haematologica. 2019 Jul 9. pii: haematol.2018.205849. doi: 10.3324/haematol.2018.205849. Junk SV, Klein N, Schreek S, Zimmermann M, Möricke A, Bleckmann K, Alten J, Dagdan E, Cario G, Kratz CP, Schrappe M, Stanulla M
- Haematologica HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M
- Haematologica Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish. Haematologica. 2019 Jul 9. pii: haematol.2019.215939. doi: 10.3324/haematol.2019.215939. Xu M, Ye Y, Ye Z, Xu S, Liu W, Xu J, Zhang Y, Liu Q, Huang Z, Zhang W
- Haematologica Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation. Haematologica. 2019 Jul 9. pii: haematol.2018.214379. doi: 10.3324/haematol.2018.214379. Boutin L, Arnautou P, Trignol A, Ségot A, Farge T, Desterke C, Soave S, Clay D, Raffoux E, Sarry JE, Malfuson JV, Lataillade JJ, Le Bousse-Kerdilès MC, Anginot A
- Haematologica Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica. 2019 Jul 9. pii: haematol.2019.218677. doi: 10.3324/haematol.2019.218677. Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ
- Haematologica How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica. 2019 Jul 4. pii: haematol.2018.208454. doi: 10.3324/haematol.2018.208454. Short NJ, Ravandi F
- Haematologica A tale of two genes: a new connection between NIPBL and NPM1 in acute myeloid leukemia. 104(7):1289-1291 Garfinkle EAR, Gruber TA
- Haematologica Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? 104(7):1302-1308 Cummins KD, Gill S
- Haematologica LEF-1 drives aberrant β-catenin nuclear localization in myeloid leukemia cells. 104(7):1365-1377 Morgan RG, Ridsdale J, Payne M, Heesom KJ, Wilson MC, Davidson A, Greenhough A, Davies S, Williams AC, Blair A, Waterman ML, Tonks A, Darley RL
- Haematologica Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia. 104(7):1378-1387 Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M
- Haematologica The side population enriches for leukemia-propagating cell activity and Wnt pathway expression in zebrafish acute lymphoblastic leukemia. 104(7):1388-1395 Baeten JT, Waarts MR, Pruitt MM, Chan WC, Andrade J, de Jong JLO
- Haematologica Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. 104(7):1396-1406 Zaliova M, Stuchly J, Winkowska L, Musilova A, Fiser K, Slamova M, Starkova J, Vaskova M, Hrusak O, Sramkova L, Stary J, Zuna J, Trka J
- Haematologica ERG deletions in childhood acute lymphoblastic leukemia with DUX4 rearrangements are mostly polyclonal, prognostically relevant and their detection rate strongly depends on screening method sensitivity. 104(7):1407-1416 Zaliova M, Potuckova E, Hovorkova L, Musilova A, Winkowska L, Fiser K, Stuchly J, Mejstrikova E, Starkova J, Zuna J, Stary J, Trka J
- Haematologica Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study. 104(7):e293-e295 Klil-Drori AJ, Yin H, Azoulay L, Harnois M, Gratton MO, Busque L, Assouline SE; Groupe Québécois de Recherche en Leucémie Myéloïde Chronique et Néoplasies Myéloprolifératives (GQR LMC-NMP)
- Haematologica miR-101 suppresses the development of MLL-rearranged acute myeloid leukemia. 104(7):e296-e299 Gonzales-Aloy E, Connerty P, Salik B, Liu B, Woo AJ, Haber M, Norris MD, Wang J, Wang JY
- Haematologica Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. 104(7):e300-e303 Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS
- Haematologica Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis. 104(7):e304-e306 Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, Ho AD, Müller-Tidow C, Dreger P
- Haematologica A novel germline SAMD9L mutation in a family with ataxia-pancytopenia syndrome and pediatric acute lymphoblastic leukemia. 104(7):e318-e321 Cheah JJC, Brown AL, Schreiber AW, Feng J, Babic M, Moore S, Young CC, Fine M, Phillips K, Guandalini M, Wilson P, Poplawski N, Hahn CN, Scott HS
- Haematologica The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293). 104(7):e330 Eskazan AE, Soysal T
- J Clin Oncol Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol. 2019 Jul 11:JCO1900894. doi: 10.1200/JCO.19.00894. Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T
- J Clin Oncol Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 Jul 8:JCO1900261. doi: 10.1200/JCO.19.00261. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG
- J Clin Oncol More Is Not Always Better: The Perils of Treatment Intensification in Pediatric Acute Lymphoblastic Leukemia. 37(19):1601-1603 Hunger SP
- J Clin Oncol Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. 37(19):1638-1646 Albertsen BK, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, Frandsen TL, Wolthers BO, Heyman M, Schmiegelow K
- Lancet Haematol On the BALL to spot the best score able to predict overall survival in relapsed or refractory CLL. 6(7):e343-e344 Ysebaert L
- Lancet Haematol Therapy de-escalation before stopping in chronic myeloid leukaemia. 6(7):e345-e346 Mustjoki S
- Lancet Haematol Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. 6(7):e366-e374 Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD
- Lancet Haematol De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. 6(7):e375-e383 Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M
- Lancet Oncol Clofarabine and cytarabine for acute myeloid leukaemia. Lancet Oncol. 2019 Jul 4. pii: S1470-2045(19)30452-8. doi: 10.1016/S1470-2045(19)30452-8. Stirrups R
- Lancet Oncol Oral targeted agent versus chemotherapy in acute myeloid leukaemia. 20(7):896-898 Röllig C, Berdel WE
- Lancet Oncol Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. 20(7):984-997 Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ
- Leukemia Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2019 Jul 12. doi: 10.1038/s41375-019-0485-x. Bisaillon R, Moison C, Thiollier C, Krosl J, Bordeleau ME, Lehnertz B, Lavallée VP, MacRae T, Mayotte N, Labelle C, Boucher G, Spinella JF, Boivin I, D'Angelo G, Lavallée S, Marinier A, Lemieux S, Hébert J, Sauvageau G
- Leukemia Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia. 2019 Jul 12. doi: 10.1038/s41375-019-0513-x. Yosifov DY, Idler I, Bhattacharya N, Reichenzeller M, Close V, Ezerina D, Scheffold A, Jebaraj BMC, Kugler S, Bloehdorn J, Bahlo J, Robrecht S, Eichhorst B, Fischer K, Weigel A, Busch H, Lichter P, Döhner H, Dick TP, Stilgenbauer S, Mertens D
- Leukemia Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome. Leukemia. 2019 Jul 11. doi: 10.1038/s41375-019-0514-9. de Smith AJ, Walsh KM, Morimoto LM, Francis SS, Hansen HM, Jeon S, Gonseth S, Chen M, Sun H, Luna-Fineman S, Antillón F, Girón V, Kang AY, Smirnov I, Shao X, Whitehead TP, Barcellos LF, Jolly KW, Healy J, Laverdière C, Sinnett D, Taub JW, Birch JM, Thompson PD, Pombo-de-Oliveira MS, Spector LG, DeWan AT, Mueller BA, Chiang C, Metayer C, Ma X, Wiemels JL
- Leukemia Chronic myeloid leukemia stem cells. 33(7):1543-1556 Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, Saglio G, Gale RP
- Leukemia NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. 33(7):1557-1569 Lopez-Millan B, Sanchéz-Martínez D, Roca-Ho H, Gutiérrez-Agüera F, Molina O, Diaz de la Guardia R, Torres-Ruiz R, Fuster JL, Ballerini P, Suessbier U, Nombela-Arrieta C, Bueno C, Menéndez P
- Leukemia Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL. 33(7):1570-1582 Hohtari H, Brück O, Blom S, Turkki R, Sinisalo M, Kovanen PE, Kallioniemi O, Pellinen T, Porkka K, Mustjoki S
- Leukemia Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. 33(7):1583-1597 Kollmann S, Grundschober E, Maurer B, Warsch W, Grausenburger R, Edlinger L, Huuhtanen J, Lagger S, Hennighausen L, Valent P, Decker T, Strobl B, Mueller M, Mustjoki S, Hoelbl-Kovacic A, Sexl V
- Leukemia Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. 33(7):1598-1607 Efficace F, Breccia M, Avvisati G, Cottone F, Intermesoli T, Borlenghi E, Carluccio P, Rodeghiero F, Fabbiano F, Luppi M, Romani C, Sborgia M, D'Ardia S, Nobile F, Cantore N, Crugnola M, Nadali G, Vignetti M, Amadori S, Lo Coco F
- Leukemia CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. 33(7):1608-1619 Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, Nerlov C, Valent P, Grembecka J, Grebien F
- Leukemia Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. 33(7):1620-1634 Mrózek K, Eisfeld AK, Kohlschmidt J, Carroll AJ, Walker CJ, Nicolet D, Blachly JS, Bill M, Papaioannou D, Wang ES, Uy GL, Kolitz JE, Powell BL, Blum W, Stone RM, Byrd JC, Bloomfield CD
- Leukemia Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. 33(7):1650-1662 Shi Y, Wang G, Muhowski EM, McCaw L, Wang C, Bjarnason G, Woyach JA, Spaner DE
- Leukemia Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. 33(7):1663-1674 Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W
- Leukemia The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. 33(7):1700-1712 Hoang VT, Verma D, Godavarthy PS, Llavona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Müller-Kuller U, Weissenberger E, Voutsinas JM, Oehler VG, Farin HF, Zörnig M, Krause DS
- Leukemia Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. 33(7):1801-1805 Moysiadis T, Baliakas P, Rossi D, Catherwood M, Strefford JC, Delgado J, Anagnostopoulos A, Belessi C, Stavroyianni N, Pospisilova S, Oscier D, Gaidano G, Campo E, Rosenquist R, Ghia P, Stamatopoulos K
- Leukemia Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia. 33(7):1805-1810 Krombholz CF, Gallego-Villar L, Sahoo SS, Panda PK, Wlodarski MW, Aumann K, Hartmann M, Lipka DB, Daskalakis M, Plass C, Niemeyer CM, Erlacher M, Flotho C
- Leukemia Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. 33(7):1814-1816 Guénot C, Lacombe F, Allou K, Dumezy F, Feuillard J, Geneviève F, Guérin E, Guy J, Maynadié M, Ballon OW, Preudhomme C, Baruchel A, Dombret H, Ifrah N, Béné MC; Groupe d’Etude Immunologique des Leucémies (GEIL)
- Leukemia GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations. 33(7):1827-1832 Sportoletti P, Celani L, Varasano E, Rossi R, Sorcini D, Rompietti C, Strozzini F, Del Papa B, Guarente V, Spinozzi G, Cecchini D, Bereshchenko O, Haferlach T, Martelli MP, Falzetti F, Falini B
Lymphoma
- Blood Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019 Jul 12. pii: blood.2019000258. doi: 10.1182/blood.2019000258. Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, Gerrie AS, Ferguson D, Cafferty F, Slack GW, Farinha P, Skinnider B, Connors JM, Sehn LH
- Blood Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study. Blood. 2019 Jul 10. pii: blood.2019001088. doi: 10.1182/blood.2019001088. Luminari S, Merli M, Rattotti S, Tarantino V, Marcheselli L, Cavallo F, Varettoni M, Bianchi B, Merli F, Tedeschi A, Cabras G, Re F, Visco C, Delamain MT, Cencini E, Spina M, Ferrero S, Ferrari A, Deodato M, Mannina D, Annibali O, Rago A, Orsucci L, Defrancesco I, Frigeni M, Cesaretti M, Arcaini L
- Blood Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood. 2019 Jul 10. pii: blood.2019001126. doi: 10.1182/blood.2019001126. Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E, Sarkozy C, Gascoyne RD, Connors JM, Ben Neriah S, Mungall A, Marra MA, Siebert R, Scott DW, Savage KJ, Steidl C
- Blood Single-cell-MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis. Blood. 2019 Jul 10. pii: blood.2019000022. doi: 10.1182/blood.2019000022. Tan WJ, Wang MM, Ricciardi-Castagnoli P, Tang T, Chee SP, Lim TS, Chan ASY
- Blood CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma. Blood. 2019 Jul 1. pii: blood.2018883421. doi: 10.1182/blood.2018883421. Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ
- Blood A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening. 134(2):171-185 Zhang JP, Song Z, Wang HB, Lang L, Yang YZ, Xiao W, Webster DE, Wei W, Barta SK, Kadin ME, Staudt LM, Nakagawa M, Yang Y
- Blood PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. 134(1):22-29 Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF
- Br J Haematol Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia. Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089. Domínguez-Pinilla N, Martínez-Zamorano E, Campos-Martín Y, Algara Plana P, Ignacio González-Granado L, Zamora Gómez M, Mollejo Villanueva M
- Br J Haematol Diagnosis of intravascular large B-cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years. Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16081. Matsue K, Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Miura D, Takeuchi K
- Br J Haematol Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era. Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16090. Prusila REI, Sorigue M, Jauhiainen J, Mercadal S, Postila A, Salmi P, Tanhua T, Tikkanen S, Kakko S, Kuitunen H, Pollari M, Nystrand I, Kuusisto MEL, Vasala K, Jantunen E, Korkeila E, Karihtala P, Sancho JM, Turpeenniemi-Hujanen T, Kuittinen O
- Br J Haematol Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. Br J Haematol. 2019 Jul 1. doi: 10.1111/bjh.16082. Yordanova K, Stilgenbauer S, Bohle RM, Lesan V, Thurner L, Kaddu-Mulindwa D, Bittenbring JT, Scharberger M, Aßmann G, Bewarder M
- Br J Haematol Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. 186(2):255-262 Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ
- Br J Haematol Cutaneous flushing associated with Hodgkin lymphoma. 186(1):9 Liu F, Kang L, Wang Y
- Br J Haematol Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. 186(1):45-53 Burkart M, Schieber M, Basu S, Shah P, Venugopal P, Borgia JA, Gordon L, Karmali R
- Haematologica Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression. Haematologica. 2019 Jul 11. pii: haematol.2019.219543. doi: 10.3324/haematol.2019.219543. Federmann B, Frauenfeld L, Pertsch H, Borgmann V, Steinhilber J, Bonzheim I, Fend F, Quintanilla-Martinez L
- Haematologica Long-term eradication of extranodal NK/T cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo. Haematologica. 2019 Jul 11. pii: haematol.2019.223511. doi: 10.3324/haematol.2019.223511. Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi H, Komatsu N
- Haematologica Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica. 2019 Jul 11. pii: haematol.2018.211904. doi: 10.3324/haematol.2018.211904. Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, Lammerts van Bueren J, Chiu C, Doshi P, Pérez-Galán P
- Haematologica EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma. Haematologica. 2019 Jul 9. pii: haematol.2019.222935. doi: 10.3324/haematol.2019.222935. Xie S, Wei F, Sun YM, Gao YL, Pan LL, Tan MJ, Wang SD, Ding J, Chen Y
- Haematologica Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with MYC and BCL2 rearrangements. 104(7):1417-1421 Uchida A, Isobe Y, Asano J, Uemura Y, Hoshikawa M, Takagi M, Miura I
- Haematologica Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. 104(7):1428-1439 Torossian A, Broin N, Frentzel J, Daugrois C, Gandarillas S, Saati TA, Lamant L, Brousset P, Giuriato S, Espinos E
- Haematologica The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. 104(7):e307-e309 Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, Stathis A, Bertoni F
- Haematologica Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system. 104(7):e326-e329 Barranco GI, Fernández S, Oña R, González-Rincón J, Martínez-Ramírez A, Teijo A, Camacho FI, Pinedo FJ, Sánchez-Beato M, Pedrosa L, de la Fuente A, Estévez M, Iglesias R, Montalbán C, García JF
- J Clin Oncol Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2019 Jul 8:JCO1900525. doi: 10.1200/JCO.19.00525. Ehrhardt MJ, Chen Y, Sandlund JT, Bluhm EC, Hayashi RJ, Becktell K, Leisenring WM, Metzger ML, Ness KK, Krull KR, Oeffinger KC, Gibson TM, Cairo MS, Gross TG, Robison LL, Armstrong GT, Yasui Y, Hudson MM, Mulrooney DA
- J Clin Oncol Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. 37(20):1732-1741 Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P, Townsend W, Culligan D, Popova B, Clifton-Hadley L, McMillan A, Hoskin P, O'Doherty MJ, Illidge T, Radford J
- Lancet Haematol Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019 Jul 8. pii: S2352-3026(19)30089-4. doi: 10.1016/S2352-3026(19)30089-4. Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R
- Lancet Oncol Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. 20(7):998-1010 Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP
- Lancet Oncol Leptomeningeal metastasis of classical Hodgkin lymphoma in a patient with malignant posterior reversible encephalopathy syndrome. 20(7):e397 Kim DD, Budhram A, Haji FA, Leung A, Khaw A, Ramsay D
- Leukemia Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. 33(7):1675-1686 Vekaria PH, Kumar A, Subramaniam D, Dunavin N, Vallurupalli A, Schoenen F, Ganguly S, Anant S, McGuirk JP, Jensen RA, Rao R
- Leukemia Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. 33(7):1687-1699 Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, Tanaka H, Chiba K, Watatani Y, Kakiuchi N, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Sanada M, Onozawa M, Teshima T, Yoshiki Y, Ishida T, Suzuki K, Shimada K, Tomita A, Kato M, Ota Y, Izutsu K, Demachi-Okamura A, Akatsuka Y, Miyano S, Yoshino T, Gaulard P, Hermine O, Takeuchi K, Ohshima K, Ogawa S
- Leukemia Characteristic gene alterations in primary gastrointestinal T- and NK-cell lymphomas. 33(7):1797-1832 Lee G, Ryu HJ, Choi JW, Kang H, Yang WI, Yang IS, Seo MK, Kim S, Yoon SO
Myeloma
- Blood Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma. Blood. 2019 Jul 3. pii: blood.2019000667. doi: 10.1182/blood.2019000667. Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San Miguel J
- Blood Facing lenalidomide-refractory myeloma. 134(2):99-101 Cavo M
- Blood A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. 134(2):123-133 Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K
- Blood Myeloma sleeper agent in myeloid disguise. 134(1):3-4 Dhakal B, Janz S
- Blood A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. 134(1):30-43 Khoo WH, Ledergor G, Weiner A, Roden DL, Terry RL, McDonald MM, Chai RC, De Veirman K, Owen KL, Opperman KS, Vandyke K, Clark JR, Seckinger A, Kovacic N, Nguyen A, Mohanty ST, Pettitt JA, Xiao Y, Corr AP, Seeliger C, Novotny M, Lasken RS, Nguyen TV, Oyajobi BO, Aftab D, Swarbrick A, Parker B, Hewett DR, Hose D, Vanderkerken K, Zannettino ACW, Amit I, Phan TG, Croucher PI
- Br J Haematol Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data. Br J Haematol. 2019 Jul 12. doi: 10.1111/bjh.16095. Chan H, Chai K, Shih S, Lewsey R, Chen K, McDiarmid B, Jackson S, Simpson D
- Br J Haematol Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. 186(1):37-44 Sverrisdóttir IS, Lund SH, Turesson I, Björkholm M, Goldin LR, Landgren O, Kristinsson SY
- Haematologica Kinome expression profiling to target new therapeutic avenues in multiple myeloma. Haematologica. 2019 Jul 9. pii: haematol.2018.208306. doi: 10.3324/haematol.2018.208306. de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, Vincent L, Seckinger A, Cartron G, Hose D, De Bruyne E, Kassambara A, Pasero P, Moreaux J
- Haematologica Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy. Haematologica. 2019 Jul 9. pii: haematol.2019.218289. doi: 10.3324/haematol.2019.218289. Tong J, Xu X, Zhang Z, Ma C, Xiang R, Liu J, Xu W, Wu C, Li J, Zhan F, Wu Y, Yan H
- Haematologica A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA
- Haematologica Clonal evolution in myeloma: a narrow road to remission. 104(7):1292-1293 Miething CC
- Haematologica Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. 104(7):1440-1450 Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG
- Haematologica PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. 104(7):e310-e313 Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK
- J Clin Oncol Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma. 37(19):1598-1600 Shaw BE, D'Souza A, Lee SJ
- J Clin Oncol Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. 37(19):1617-1628 Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group
- J Clin Oncol Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. 37(19):1657-1665 Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J
- Lancet Registering a CD38 antibody upfront for multiple myeloma. 394(10192):3-4 Hofmeister CC, Nooka A, Kaufman JL, Lonial S
- Lancet Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. 394(10192):29-38 Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
- Lancet Oncol Combined treatment for multiple myeloma. 20(7):e349 Das M
- Leukemia Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. 33(7):1713-1722 Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N
- Leukemia Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. 33(7):1736-1746 Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG
- Leukemia Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma. 33(7):1817-1821 Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A
SCT
- Blood Selection of Unrelated Donors and Cord Blood Units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR. Blood. 2019 Jul 10. pii: blood.2019001212. doi: 10.1182/blood.2019001212. Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina MA, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J
- Blood Fertility Preservation in Patients with Hematologic Malignancies and Recipients of Hematopoietic Cell Transplants. Blood. 2019 Jul 10. pii: blood.2018846790. doi: 10.1182/blood.2018846790. Loren AW, Senapati S
- Blood Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. 134(2):211-215 Chen YB, Elias N, Heher E, McCune JS, Collier K, Li S, Del Rio C, El-Jawahri A, Williams W, Tolkoff-Rubin N, Fishman JA, McAfee S, Dey BR, DeFilipp Z, O'Donnell PV, Cosimi AB, Sachs D, Kawai T, Spitzer TR
- Blood PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. 134(1):22-29 Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF
- Br J Haematol Adult hypodiploid B-acute lymphoblastic leukaemia and stem cell transplantation. 186(2):205-206 Wiernik PH
- Br J Haematol G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. 186(1):60-71 Schneidawind C, Jahnke S, Schober-Melms I, Schumm M, Handgretinger R, Faul C, Kanz L, Bethge W, Schneidawind D
- Br J Haematol Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world’s largest retrospective cohort study. 186(1):72-85 Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS
- Br J Haematol Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. 186(1):86-90 Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K
- Haematologica Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation. Haematologica. 2019 Jul 11. pii: haematol.2019.220293. doi: 10.3324/haematol.2019.220293. Radujkovic A, Kordelas L, Krzykalla J, Benner A, Schult D, Majer-Lauterbach J, Beelen DW, Müller-Tidow C, Kasperk C, Dreger P, Luft T
- Haematologica Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2019 Jul 11. pii: haematol.2019.223503. doi: 10.3324/haematol.2019.223503. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR
- Haematologica The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation. 104(7):1309-1321 Copsel S, Wolf D, Komanduri KV, Levy RB
- Haematologica Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. 104(7):1322-1331 Khawaja F, Chemaly RF
- Haematologica A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. 104(7):e314-e317 Paul J, Nakasone H, Sahaf B, Wu F, Wang K, Ho V, Wu J, Kim H, Blazar B, Ritz J, Howard A, Cutler C, Miklos D
- J Clin Oncol Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. 37(19):1617-1628 Ahmedzai SH, Snowden JA, Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, Dhanapal V, Jenner M, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Parrish C, Brown JM, Morris TCM, Cook G; National Cancer Research Institute Haemato-Oncology Clinical Studies Group
- Lancet Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. 394(10192):29-38 Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P
HSC
- Br J Haematol Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world’s largest retrospective cohort study. 186(1):72-85 Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS
- Br J Haematol Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. 186(1):86-90 Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K
- Haematologica In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A. Haematologica. 2019 Jul 11. pii: haematol.2019.219089. doi: 10.3324/haematol.2019.219089. Wang D, Zhang G, Gu J, Shao X, Dai Y, Li J, Pan X, Yao S, Xu A, Jin Y, Huang J, Shi Q, Zhu J, Xi X, Chen Z, Chen S
- Haematologica Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Haematologica. 2019 Jul 9. pii: haematol.2018.214866. doi: 10.3324/haematol.2018.214866. Hetzel M, Lopez-Rodriguez E, Mucci A, Nguyen AHH, Suzuki T, Shima K, Buchegger T, Dettmer S, Rodt T, Bankstahl JP, Malik P, Knudsen L, Schambach A, Hansen G, Trapnell BC, Lachmann N, Moritz T
- Haematologica The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation. 104(7):1309-1321 Copsel S, Wolf D, Komanduri KV, Levy RB
- Haematologica Bone marrow niches of germline FANCC/FANCG deficient mice enable efficient and durable engraftment of hematopoietic stem cells after transplantation. 104(7):e284-e287 Zha J, Kunselman L, Fan JM, Olson TS
Bone marrow failure
- このキーワードに関連した論文はありません
ITP
- Haematologica Blood transcriptome and clonal T cell correlates of response and nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. Haematologica. 2019 Jul 11. pii: haematol.2019.226688. doi: 10.3324/haematol.2019.226688. Zhang H, Zhang BM, Guo X, Xu L, You X, West RB, Bussel JB, Zehnder JL
- Haematologica Anti-glycoprotein Ibα autoantibodies do not impair circulating thrombopoietin levels in immune thrombocytopenia patients. Haematologica. 2019 Jul 11. pii: haematol.2019.228908. doi: 10.3324/haematol.2019.228908. Porcelijn L, Schmidt DE, van der Schoot CE, Vidarsson G, de Haas M, Kapur R